Akebia Therapeutics, Inc. (NASDAQ:AKBA) has a Return on Invested Capital (ROIC) of 0.34% and a Weighted Average Cost of Capital (WACC) of 10.46%, indicating inefficiencies in capital utilization.Ardelyx, Inc. (NASDAQ:ARDX) shows a slightly better ROIC to WACC ratio compared to its peers, despite it being negative.FibroGen, Inc. (NASDAQ:FGEN), Karyopharm Therapeutics Inc. (NASDAQ:KPTI), Calithera Biosciences, Inc. (NASDAQ:CALA), and Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) face significant challenges in gene ...